Event date:
Friday, 9 July, 2021
Vect-Horus and RadioMedix are pleased to announce the FDA clearance of exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the detection and mapping of Low Density Lipoprotein Receptor (LDLR) overexpressed in Glioblastoma Multiforme (GBM).
To learn more visit the article in the BUSINESS WIRE site
